SAB Biotherapeutics presents a speculative, pre-revenue biotech profile in which revenue disappeared entirely after 2024Q4 ($114.7K) while R&D expense nearly doubled from $8.1M in 2024Q1 to $16.2M in 2026Q2, widening quarterly operating losses from -$10.0M to -$23.4M.
Price trend, volume and key moving averages
Trailing total returns as of 11/8/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC).
Recent results and news deserve attention only when they alter the forward view.
| Quarter | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|
Q4 2026Latest Nov 5, 2026 | -$0.24+12.6% vs -$0.27 | — vs $125,000 |
Q3 2026 Aug 6, 2026 | -$0.28+1.1% vs -$0.28 | — vs $125,000 |
Q2 2026 May 12, 2026 | -$0.35-75.0% vs -$0.20 | — vs $125,000 |
Q2 2026 Mar 9, 2026 | -$0.46-187.5% vs -$0.16 | — vs $100,000 |
SAB Biotherapeutics NASDAQ: SABS reaffirmed its timeline for completing enrollment in its pivotal Type 1 diabetes study by the end of 2026, as the company reported a wider research spending bill and a third-quarter net loss.
SAB Biotherapeutics, Inc. (SABS) Q3 2026 Earnings Call Transcript
Adult and adolescent cohorts fully enrolled in registrational SAFEGUARD study of SAB-142; Pediatric cohort (ages 5–11) actively enrolling with overall enrollment on track for completion in Q4 2026
MIAMI, Oct. 29, 2026 (GLOBE NEWSWIRE) -- SAB Biotherapeutics, Inc. (Nasdaq: SABS), a clinical-stage biopharmaceutical company developing a fully human anti-thymocyte immunoglobulin (hATG) for type 1 diabetes (T1D) and other autoimmune diseases, today announced that its third quarter 2026 financial results will be issued on the morning of Thursday, November 5, 2026. Management will host a conference call and webcast at 08:30 AM ET to discuss the results and provide business updates.
Benchmark SABS against direct peers instead of judging its metrics in isolation.
Key metrics vs top competitors for SAB Biotherapeutics, Inc. (SABS)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $3.03 | $282.51M | -3.51 | -100% | — | -40.04% | — | |
| $30.53 | $6.3B | -11.66 | — | -7585.86% | -69.59% | — | |
| $927.21 | $60.16B | 47.23 | 89.64% | — | — | — | |
| $103.63 | $12.29B | 26.18 | 37.55% | 26.93% | 544.26% | — | |
| $12.73 | $2.95B | 15.76 | 19.63% | 35.14% | 42.56% | — | |
| $10.54 | $886.31M | -15.16 | — | — | -34.98% | — |
SAB Biotherapeutics, Inc. (SABS) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
Verify the primary filings, follow material updates, and answer the remaining questions.
SAB Biotherapeutics, Inc. (SABS) SEC filings — annual & quarterly reports (10-K, 10-Q)
Jul 7, 2026·SEC
Jun 18, 2026·SEC
May 4, 2026·SEC
Get notified when SABS posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
SAB Biotherapeutics, Inc. (SABS) stock FAQ — growth, dividends, profitability & financials explained
SAB Biotherapeutics, Inc. (SABS) revenue fell by 100.0% over the trailing twelve months, compared with the twelve months before.
No. SAB Biotherapeutics, Inc. (SABS) reported a net loss of $80.5M over the trailing twelve months.
SAB Biotherapeutics, Inc. (SABS) had a return on equity (ROE) of -40.0% over the trailing twelve months. A negative ROE means the company lost money over the period.
SAB Biotherapeutics, Inc. (SABS) had negative free cash flow of $74.0M over the trailing twelve months.
